Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 1999

View Archived Issues

PPL Therapeutics overviews corporate restructuring, updates product pipeline

Orion reports interim results and progress

ImmunoGen options antibody from Duke and Johns Hopkins

DGT and Immunex renew IBD collaboration

Protein Design Labs highlights progress during 3rd quarter

Pharmacopeia and Otsuka enter drug discovery collaboration

Gemifloxacin active in vitro against anaerobes

Phase II trials initiated with MRE-0470 as CAD diagnostic

AVI BioPharma files IND with FDA for Resten-NG

Angiotech commences phase II clinical study of micellar paclitaxel in SPMS

Somatostatin receptor ligands synthesized and tested at Takeda

Pfizer's new 5-HT1 ligands useful for CNS and related disorders

Dihydropyrimidines for hepatitis B designed at Bayer

Wide series of GH-stimulating compounds presented by Novo Nordisk

Agents for Alzheimer's disease from Schering-Plough acting as muscarinic antagonists

New antibacterial agents from Bayer exert good activity against staphylococci

Celgene presents new TNF-alpha inhibitor and preliminary clinical results at AAPS meeting

Pharmacokinetic profiles of two oral AII antagonists described by Pfizer at AAPS

FDA requests confirmatory trial of Aldurazyme prior to BLA filing

Bosentan safe and effective in CHF during open-label extension of REACH-1

AAPS presentation for new beta3-adrenoceptor agonist: preclinical PK/PD of GW-0604

Pharmacokinetics of CP-331684 investigated in animal species

Tezosentan is safe and produces beneficial vasodilatory responses in patients with CHF

Detailed pharmacokinetics, pharmacodynamics and toxicokinetics reported for CI-1027

Ribozyme and Chiron initiate phase I/II studies of Angiozyme

Immune Response reports success with novel RA treatment approach

Entecavir: absorption, distribution, metabolism and excretion assessed in preclinical studies

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026